Proteomics Gives Us the Cancer Traffic Report
-
By
-
Kayla Sparks
-
Emanuel "Chip" Petricoin
-
September 3, 2026
-
12 min
By
Kayla Sparks
Emanuel "Chip" Petricoin
September 3, 2026
by Kayla Sparks, Emanuel "Chip" Petricoin
September 3, 2026
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
Researchers identified gaps in molecular diagnostics, drug susceptibility testing, and treatment monitoring
September 3, 2026
A smartphone-linked fluorimeter detects infectious disease and cancer biomarkers in 10-minute assays
August 31, 2026